Herbert H Loong
Overview
Explore the profile of Herbert H Loong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gautschi O, Park K, Solomon B, Tomasini P, Loong H, De Braud F, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402076.
PMID: 39983053
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety...
2.
Liu J, Farrow M, Seymour L, Desai J, Loong H, Ivy P, et al.
J Clin Oncol
. 2025 Jan;
43(6):735-747.
PMID: 39808749
Purpose: Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors,...
3.
Giani C, Salawu A, Ljevar S, Denu R, Napolitano A, Palmerini E, et al.
Am J Surg Pathol
. 2024 Oct;
49(1):27-34.
PMID: 39466087
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS,...
4.
Yeung M, Liu A, Wong S, Loong H, Shek T
Mod Pathol
. 2024 Oct;
38(1):100635.
PMID: 39442668
GLI1-altered mesenchymal tumors have recently emerged as a distinctive group of neoplasms characterized by GLI1 fusions or amplifications. Although there is clearly metastatic potential, the clinicopathologic features predicting for metastasis...
5.
Zhang Y, Wong C, Hui C, Tse T, Yeung V, Cheung K, et al.
Biomed Pharmacother
. 2024 Jun;
176:116895.
PMID: 38876055
Background: Soft tissue sarcomas (STS) are rare diseases typically arising from connective tissues in children and adults. However, chemotherapies involved in the treatment of STS may cause toxic side effects...
6.
Repetto M, Garassino M, Loong H, Lopez-Rios F, Mok T, Peters S, et al.
Cancer Treat Rev
. 2024 May;
127:102733.
PMID: 38733648
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed...
7.
Ang Y, Zhao X, Reungwetwattana T, Cho B, Liao B, Yeung R, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894366
Epidermal growth factor receptor () T790M mutations drive resistance in 50% of patients with advanced non-small cell lung cancer (NSCLC) who progress on first/second generation (1G/2G) EGFR tyrosine kinase inhibitors...
8.
Zhou C, Solomon B, Loong H, Park K, Perol M, Arriola E, et al.
N Engl J Med
. 2023 Oct;
389(20):1839-1850.
PMID: 37870973
Background: Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced fusion-positive non-small-cell lung cancer (NSCLC) in a nonrandomized phase 1-2 study....
9.
El Helali A, Lam T, Ko E, Shih D, Chan C, Wong C, et al.
Lancet Reg Health West Pac
. 2023 Aug;
36:100775.
PMID: 37547050
Background: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB)...
10.
Loong H, Gupta A, Gronchi A
Ann Surg Oncol
. 2023 Mar;
30(5):2570-2573.
PMID: 36907961
No abstract available.